

23 July 2020 Sydney, Australia

Noxopharm Discusses Converting Cold to Hot Cancer Tumours

Sydney, 23 July 2020: Noxopharm (ASX:NOX) releases an FNN interview in which the Executive Chairman and CEO, Dr Graham Kelly, explains further the Company's important recent pre-clinical data concerning the conversion of cancer tumours from 'Cold' to 'Hot' tumours.

Link to the interview:

https://www.finnewsnetwork.com.au/MediaCenter/MediaCenterMobile.aspx?Site=FNN1834

The interview can also be found at: https://www.noxopharm.com/site/investors/presentations

The related ASX announcement from 20 July 2020 can be found here:

https://www.asx.com.au/asxpdf/20200720/pdf/44knkx9383q3tr.pdf

About Noxopharm

Noxopharm is a clinical-stage Australian drug development company with offices in Sydney and New York. The Company has a primary focus on the development of Veyonda® and is the major shareholder in U.S. biotechnology company, Nyrada Inc. (ASX:NYR).

www.noxopharm.com

Investor & Corporate enquiries:

Prue Kelly M: 0459 022 445

E: info@noxopharm.com

Company Secretary:

David Franks T: +61 2 8072 1400

E: David.Franks@automicgroup.com.au

Graham Kelly, CEO and Chairman of Noxopharm, has approved the release of this document to the market.

Forward Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as "aim", "anticipate", "assume", "believe", "continue", "could", "estimate", "expect", "intend", "may", "plan", "predict", "project", "plan", "should", "target", "will" or "would" or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company's control that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement.